NYSE: NUS
NU SKIN ENTERPRISES, INC.CIK 0001021561 · SIC 5122 · Drugs & Sundries
Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of premium-quality beauty and wellness solutions in nearly 50 markets worldwide. In 2025, our revenue of $1.5 billion was primarily generated by our two primary product categories: beauty products and wellness products. We… About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (CRWD 10-Q) is open in full — no account needed.
Summary not yet generated.
Nu Skin reports Q2 revenue down 17%, posts $5.14 loss on impairment and tax charges
5 material changes detected. Sign up free to read the summary.
Partner
Trade NUS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Revenue fell 17.1% to $320.1M; goodwill impairment and tax allowance drove Q2 EPS to $(5.14)
5 material changes detected. Sign up free to read the summary.
Nu Skin stockholders approve equity plan adding 2.85M shares, extending term to 2036
3 material changes detected. Sign up free to read the summary.
Nu Skin Chief Product Officer Steven Hatchett resigns for family health reasons
2 material changes detected. Sign up free to read the summary.
Nu Skin Q1 revenue falls 12% to $320.6M; exits BeautyBio, refinances debt, strips tariff risk
5 material changes detected. Sign up free to read the summary.
Nu Skin announces Q1 2026 financial results in earnings press release
1 material change detected. Sign up free to read the summary.
Nu Skin refinances credit facility with $175M term loan and $75M revolver
5 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 10, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | 320,112 | 386,138 | 640,720 | 750,628 |
| Cost of sales | 101,787 | 120,405 | 207,932 | 237,934 |
| Gross profit | 218,325 | 265,733 | 432,788 | 512,694 |
| Operating expenses: | ||||
| Selling expenses | 107,922 | 128,228 | 217,976 | 246,774 |
| General and administrative expenses | 90,847 | 106,725 | 189,391 | 219,929 |
| Impairment expenses | 78,875 | - | 80,714 | 25,114 |
| Total operating expenses | 277,644 | 234,953 | 488,081 | 491,817 |
| Operating income (loss) | (59,319) | 30,780 | (55,293) | 20,877 |
| Interest expense | 3,322 | 2,526 | 7,572 | 5,809 |
| Gain on sale of business | - | - | - | 176,162 |
| Other income (expense), net | (534) | (843) | 2,289 | (29,218) |
| Income (loss) before provision for income taxes | (63,175) | 27,411 | (60,576) | 162,012 |
| Provision for income taxes | 186,623 | 6,292 | 187,386 | 33,378 |
| Net income (loss) | (249,798) | 21,119 | (247,962) | 128,634 |
| Net income (loss) per share (Note 7): | ||||
| Basic | (5.14) | 0.43 | (5.12) | 2.59 |
| Diluted | (5.14) | 0.43 | (5.12) | 2.59 |
| Weighted-average common shares outstanding (000s): | ||||
| Basic | 48,596 | 49,441 | 48,400 | 49,601 |
| Diluted | 48,596 | 49,499 | 48,400 | 49,748 |
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 189,643 | 238,630 |
| Current investments | 1,743 | 1,211 |
| Accounts receivable, net | 48,902 | 39,544 |
| Inventories, net | 191,497 | 178,643 |
| Prepaid expenses and other | 76,364 | 89,670 |
| Total current assets | 508,149 | 547,698 |
| Property and equipment, net | 379,550 | 377,168 |
| Operating lease right-of-use assets | 65,442 | 74,021 |
| Goodwill | 4,750 | 83,625 |
| Other intangible assets, net | 37,884 | 42,614 |
| Other assets | 125,755 | 280,187 |
| Total assets | 1,121,530 | 1,405,313 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 37,711 | 26,183 |
| Accrued expenses | 198,636 | 217,551 |
| Current portion of long-term debt | 20,000 | 20,000 |
| Total current liabilities | 256,347 | 263,734 |
| Operating lease liabilities | 50,075 | 57,640 |
| Long-term debt | 193,664 | 204,187 |
| Other liabilities | 78,705 | 74,512 |
| Total liabilities | 578,791 | 600,073 |
| Commitments and contingencies (Notes 6 and 12) | ||
| Stockholders’ equity: | ||
| Class A common stock 500 million shares authorized, $0.001 par value, 90.6 million shares issued | 91 | 91 |
| Additional paid-in capital | 612,412 | 635,994 |
| Treasury stock, at cost 41.9 million and 42.4 million shares | (1,558,183) | (1,575,059) |
| Accumulated other comprehensive loss | (118,152) | (116,105) |
| Retained earnings | 1,606,571 | 1,860,319 |
| Total stockholders’ equity | 542,739 | 805,240 |
| Total liabilities and stockholders’ equity | 1,121,530 | 1,405,313 |
Consolidated Statements of Cash Flows (Unaudited)
(U.S. dollars in thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income (loss) | (247,962) | 128,634 |
| Adjustments to reconcile net income to cash flows from operating activities: | ||
| Gain on sale of business | - | (176,162) |
| Impairment of goodwill, fixed assets and other intangibles | 80,714 | 25,114 |
| Unrealized losses on equity investments | - | 28,077 |
| Depreciation and amortization | 25,000 | 27,258 |
| Non-cash lease expense | 12,508 | 13,055 |
| Stock-based compensation | 4,812 | 15,126 |
| Inventory write-down | 6,130 | 5,800 |
| Foreign currency losses (gains) | (254) | 2,441 |
| Loss (gain) on disposal of assets | 293 | (72) |
| Deferred taxes | 165,952 | (6,793) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (10,007) | (8,660) |
| Inventories, net | (21,260) | 10,909 |
| Prepaid expenses and other | 12,728 | 6,251 |
| Other assets | (4,342) | (7,356) |
| Accounts payable | 11,733 | (6,824) |
| Accrued expenses | (30,326) | (20,334) |
| Other liabilities | 987 | (280) |
| Net cash provided by operating activities | 6,706 | 36,184 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (19,352) | (13,602) |
| Purchases of investments | (573) | - |
| Proceeds on investment sales | - | 10,214 |
| Proceeds from sale of business, net | - | 193,725 |
| Net cash (used in) provided by investing activities | (19,925) | 190,337 |
| Cash flows from financing activities: | ||
| Exercise of employee stock options and taxes paid related to the net shares settlement of stock awards | (4,136) | (1,142) |
| Payment of cash dividends | (5,786) | (5,966) |
| Repurchases of shares of common stock | (5,011) | (5,012) |
| Finance lease principal payments | (978) | (1,120) |
| Proceeds from debt | 225,000 | 15,000 |
| Payments of debt | (235,000) | (160,000) |
| Payment of debt issuance costs | (1,369) | - |
| Purchase of noncontrolling interest | (6,500) | (1,498) |
| Other, net | - | 2,711 |
| Net cash used in financing activities | (33,780) | (157,027) |
| Effect of exchange rate changes on cash | (1,988) | 7,782 |
| Net (decrease) increase in cash and cash equivalents | (48,987) | 77,276 |
| Cash and cash equivalents, beginning of period | 238,630 | 186,883 |
| Cash and cash equivalents, end of period | 189,643 | 264,159 |
Amounts as printed on the EDGAR/iXBRL face — (U.S. dollars in thousands, except per share amounts); (U.S. dollars in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗
View AI report for this filing
About NU SKIN ENTERPRISES, INC.
Source: Item 1 (Business) from the 10-K filed February 13, 2026. Description as filed by the company with the SEC.
ITEM 1.
BUSINESS
Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of premium-quality beauty and wellness solutions in nearly 50 markets worldwide. In 2025, our revenue of
$1.5 billion was primarily generated by our two primary product categories: beauty products and wellness products. We operate in the direct selling channel, primarily utilizing person-to-person
marketing to promote and sell our products, including through the use of social and digital platforms.
In addition to our core Nu Skin business, we also explore new areas of
synergistic and adjacent growth through our strategic investment arm known as Rhyz Inc., which we formed in 2018. Our Rhyz businesses primarily consist of consumer, technology and manufacturing companies. In 2025, the Rhyz companies generated
$223.6 million, or 15%, of our 2025 reported revenue (excluding sales to our core Nu Skin business). As discussed further in “Rhyz Companies,” below, in January 2025 we sold one of our Rhyz businesses that accounted for $69.6 million of our
2024 reported revenue. Our Rhyz companies enable us to optimize our cost of goods, improve lead times, diversify our revenue mix, and create synergies for our brands.
In 2025, we generated approximately 26% of our revenue from the
United States (consisting of our Nu Skin United States and Rhyz businesses) and the remainder from our international markets. Given the size of our international operations, our results, as reported in U.S. dollars, are often impacted by
foreign-currency fluctuations; in 2025, our revenue was negatively impacted 0.8% from foreign-currency fluctuations compared to 2024. Our results also can be impacted by global economic, political, demographic and business trends and
conditions.
Read full description ↓
Our operations are subject to various laws and regulations globally, particularly with respect to our product categories and our distribution channel. See